stockportfolio.pro
BIIB vs MRNA: Which Stock Is the Better Buy?
Biogen Inc. and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BIIB vs MRNA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Biogen Inc. (BIIB) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $31.9B | $31.6B |
| Revenue (latest FY) | $9.89B | $1.94B |
| Net income (latest FY) | $1.29B | $-2.82B |
| Revenue growth (5y CAGR) | -6.0% | 19.3% |
| Net margin | 13.1% | -145.2% |
| Return on equity | 7.1% | -32.6% |
| P/E ratio | 23.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 2 |
| Positive free cash flow | Yes | No |
See the full BIIB vs MRNA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BIIB's full financials → Open MRNA's full financials →More comparisons
Frequently asked questions
Which is bigger, BIIB or MRNA?
Biogen Inc. is larger by market capitalization — $31.9B versus $31.6B.
Which grows faster, BIIB or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BIIB fundamentals → · MRNA fundamentals → · All 1,500+ companies → · Free screener →